Thrombolytics: dissolve an established fibrin clot when time matters
Thrombolytic (fibrinolytic) drugs activate plasminogen to plasmin, which breaks down fibrin within an existing thrombus. They can rapidly restore perfusion in selected, time-critical emergencies, but may cause catastrophic bleeding. Their use is hospital-based, protocol-led and never a substitute for diagnostic confirmation, contraindication screening or mechanical reperfusion where that is indicated and available.
Emergency safety rule
Before thrombolysis, exclude haemorrhage and actively search for contraindications. Suspected aortic dissection, active internal bleeding, intracranial haemorrhage, recent high-risk surgery/trauma, severe uncontrolled hypertension or a major bleeding diathesis can make treatment dangerous. For suspected stroke, urgent brain imaging is required to distinguish ischaemic from haemorrhagic stroke.
Lesson map
Plasminogen → plasmin → fibrin degradation.
Streptokinase, urokinase and tissue plasminogen activators.
STEMI, acute ischaemic stroke, massive PE and selected catheter occlusion.
Time window, imaging, bleeding, monitoring and rescue.
1. Physiological fibrinolysis and mechanism
Haemostasis forms a fibrin mesh to stabilise the platelet plug. The endogenous fibrinolytic system limits clot growth: plasminogen is incorporated into the clot and, when activated to plasmin, degrades fibrin into soluble fibrin-degradation products. Plasmin can also reduce circulating fibrinogen and other coagulation proteins, which explains the systemic bleeding risk of less fibrin-selective agents.
| Step | Key event | Clinical implication |
|---|---|---|
| Clot formation | Fibrin stabilises a platelet plug. | Antiplatelets and anticoagulants prevent extension/new clot formation; they do not directly lyse an established clot. |
| Drug activation | Thrombolytic converts plasminogen to plasmin. | Fibrin is degraded, potentially restoring blood flow. |
| Reperfusion | Occluded vessel may reopen. | Benefit decreases with delay; treat only within the appropriate indication-specific window. |
| Re-occlusion prevention | Platelets and coagulation can re-form thrombus. | Antiplatelet/anticoagulant therapy may be prescribed as part of a defined pathway, but adds bleeding risk. |
2. Classification
| Group | Examples | Key pharmacology |
|---|---|---|
| Non-fibrin-specific activators | Streptokinase, urokinase, anistreplase | Activate circulating and clot-bound plasminogen; more systemic fibrinolysis. Streptokinase is antigenic because it is streptococcal-derived. |
| Fibrin-enhanced tissue plasminogen activators (tPA) | Alteplase, reteplase, tenecteplase | Preferential activity at fibrin-rich clot; recombinant products. Fibrin selectivity does not eliminate major bleeding risk. |
| Adjunct/reversal concepts | Antifibrinolytics: tranexamic acid, aminocaproic acid | Inhibit plasminogen activation/fibrinolysis. They may be considered in serious bleeding only under specialist, indication-specific guidance. |
3. Drug profiles
| Drug | Important features | High-yield safety point |
|---|---|---|
| Streptokinase | Indirect plasminogen activator forming a streptokinase–plasminogen complex; inexpensive and non-fibrin-specific. | Fever, hypotension, allergy/anaphylaxis and neutralising antibodies can occur. Avoid repeat exposure or recent streptococcal infection according to protocol. |
| Urokinase | Direct plasminogen activator; non-antigenic. | Systemic bleeding remains the principal hazard; specialist use varies by availability and indication. |
| Alteplase | Recombinant tPA with short half-life; commonly administered in a protocolised bolus/infusion regimen. | Used in selected acute ischaemic stroke and other thrombotic emergencies; careful timing and imaging are essential. |
| Reteplase | Modified tPA with longer half-life than alteplase. | Often given in protocolled bolus dosing for selected myocardial infarction pathways. |
| Tenecteplase | Genetically modified tPA with higher fibrin specificity and longer half-life; convenient single-bolus administration. | Current stroke guidance in several settings supports tenecteplase as an alternative to alteplase for eligible acute ischaemic stroke patients; follow local protocol. |
4. Indications: match the drug to the emergency
Thrombolysis is not “one treatment for all clots.” Eligibility depends on the diagnosis, onset time, imaging, severity, available reperfusion service, comorbidities and bleeding risk.
| Condition | Role of thrombolysis | Key decision |
|---|---|---|
| Acute ischaemic stroke | IV thrombolysis may improve outcome in eligible patients within the local time window; many guidelines use up to 4.5 hours from known onset in selected adults. | Establish last-known-well time, perform urgent brain imaging, assess severity/BP/glucose/anticoagulant exposure and follow stroke-team protocol. Do not thrombolyse haemorrhagic stroke. |
| ST-elevation MI (STEMI) | Fibrinolysis may be used when timely primary PCI cannot be delivered and no contraindication exists. | ECG diagnosis, symptom timing and transfer/PCI pathway determine choice. PCI remains preferred where promptly available. |
| Massive/high-risk pulmonary embolism | May be considered for PE with haemodynamic instability/shock. | Balance life-threatening obstructive shock against bleeding; involve senior/emergency/critical-care team. |
| Acute limb-threatening arterial occlusion or catheter occlusion | Catheter-directed/local thrombolysis may be used in selected specialist settings. | Vascular/interventional radiology assessment is required; not routine self-directed systemic therapy. |
5. Pre-thrombolysis checklist
- Confirm diagnosis and timing: symptom onset/last-known-well; ECG or imaging as required. In stroke, check non-contrast brain imaging first.
- Establish baseline: ABCDE assessment, neurological findings where relevant, weight, blood pressure, blood glucose, FBC/platelets, coagulation tests and renal function as the protocol requires.
- Ask specifically about bleeding risk: previous intracranial haemorrhage, recent stroke/head injury/neurosurgery, known intracranial lesion, active bleeding, recent major surgery/trauma, peptic ulcer and pregnancy/postpartum state.
- Review antithrombotics: anticoagulants (including DOAC timing), heparin, warfarin/INR and antiplatelets. These can change eligibility.
- Exclude mimics/alternative catastrophes: haemorrhagic stroke, aortic dissection, severe uncontrolled hypertension and hypoglycaemia in suspected stroke.
- Explain and document: benefit, serious bleeding risk, consent/emergency decision process, exact drug/time, checks and escalation plan.
6. Contraindications and cautions
Absolute or major exclusions are indication-specific
Use the current local protocol; lists differ slightly between stroke, STEMI and PE. The following are major red flags that require senior review and usually exclude systemic thrombolysis.
- Active internal bleeding or known serious bleeding disorder.
- Current or previous intracranial haemorrhage; suspected subarachnoid haemorrhage; significant intracranial tumour, arteriovenous malformation or aneurysm according to protocol.
- Recent significant head trauma, intracranial/intraspinal surgery or recent major surgery/trauma.
- Severe uncontrolled hypertension; in stroke pathways BP must be within the protocol threshold before treatment.
- Marked thrombocytopenia or clinically important abnormal coagulation from anticoagulants.
- Suspected aortic dissection, active infective endocarditis, recent GI/GU bleeding or active peptic ulcer—assess the specific guideline.
- Pregnancy, early postpartum period, diabetic proliferative retinopathy and recent invasive/traumatic puncture are important relative-risk discussions, not automatic shortcuts.
7. Administration and monitoring principles
Thrombolytics are administered only in a setting equipped for immediate resuscitation, serial assessment and management of intracranial or major extracranial bleeding. Never memorise one dose across all conditions. Drug, dose, bolus/infusion method and weight limit differ by agent and indication.
| During treatment | Why it matters |
|---|---|
| Frequent vital signs, consciousness/neuro checks and bleeding inspection | Early recognition of intracranial haemorrhage, shock, allergy or reperfusion complication. |
| Avoid unnecessary IM injections, arterial punctures, urinary catheterisation and traumatic procedures | Puncture sites can become major bleeding sources; if necessary, use the safest approach and prolonged compression. |
| Monitor ECG/clinical reperfusion in STEMI and reassess neurology in stroke | Failure to reperfuse or clinical deterioration requires urgent escalation for rescue reperfusion/thrombectomy/PCI pathway. |
| Recheck FBC/coagulation/fibrinogen when bleeding is suspected or protocol directs | Guides haemorrhage management and replacement therapy. |
8. Adverse effects and emergency response
| Complication | Warning signs | Immediate principle |
|---|---|---|
| Major extracranial bleeding | Haematemesis, melaena, haematuria, heavy wound/puncture bleeding, falling BP or Hb. | Stop infusion if running, call senior/emergency team, resuscitate, obtain urgent bloods and follow the thrombolysis-bleeding protocol. |
| Intracranial haemorrhage | New severe headache, vomiting, acute hypertension, reduced consciousness, new neurological deficit or deterioration. | Stop drug, urgent brain imaging and stroke/critical-care/haematology pathway. This is a medical emergency. |
| Allergy/hypotension | Rash, bronchospasm, fever, hypotension—especially with streptokinase. | Stop drug and treat anaphylaxis/shock according to emergency protocol. |
| Reperfusion arrhythmia | Rhythm disturbance after MI reperfusion. | Continuous monitoring and ACLS-based management as appropriate. |
9. Antifibrinolytics and reversal thinking
Tranexamic acid and aminocaproic acid inhibit fibrinolysis and may be used for selected bleeding conditions. They are not routine “antidotes” to self-administer after thrombolysis. Severe bleeding after a fibrinolytic requires a specialist protocol that may include stopping antithrombotics, local haemostasis, blood products/fibrinogen replacement and carefully selected antifibrinolytic therapy. Treat the patient and the indication, not a single laboratory number.
10. High-yield cases and OSCE points
Record last-known-well time, check glucose and BP, arrange urgent CT brain, screen anticoagulants/bleeding risk and activate the stroke pathway—do not delay for a lengthy history.
Confirm STEMI, symptom time and contraindications; arrange urgent reperfusion decision and transfer. Thrombolysis is only for eligible patients when timely PCI is not feasible.
Treat as possible intracranial haemorrhage: stop treatment, urgent senior review, imaging and protocol-led resuscitation.
Ask about prior exposure/recent streptococcal infection because antibodies/allergy may alter drug selection.
- Define thrombolysis and state: plasminogen → plasmin → fibrin degradation.
- Differentiate fibrin-enhanced tPA agents from non-fibrin-specific agents.
- State the central danger: major bleeding, including intracranial haemorrhage.
- For stroke, say “image first to exclude haemorrhage; time window and protocol decide eligibility.”
- For any procedure after treatment, name unnecessary puncture/IM injection avoidance and close monitoring.
Further study
Course reference: Thrombolytic Drugs—SlideShare. Use current hospital and national protocols alongside NICE tenecteplase guidance, the BNF/NICE stroke summary, and MedlinePlus alteplase safety information. Local stroke, STEMI, PE and bleeding protocols take priority over a general learning page.
